Published retrospective studies [64,65,67,68,74] and meta-analyses [75,83] consistently demonstrate that the use of SGLT2 inhibitors is associated with a reduction in mortality among diabetic patients undergoing anthracycline-based cancer therapy. The gene discussed is SLC5A2; the disease is cancer.